{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T03:07:48Z","timestamp":1765940868314,"version":"3.48.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"vor","delay-in-days":32,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Doctor's Workshop at Zhangzhou Hospital","award":["PDB202314"],"award-info":[{"award-number":["PDB202314"]}]},{"name":"the\u00a0Natural Science Foundation of Fujian Province","award":["2021j01409"],"award-info":[{"award-number":["2021j01409"]}]},{"name":"the Science and Technology Project of Health Commission of Fujian Province","award":["2021CXA033"],"award-info":[{"award-number":["2021CXA033"]}]},{"name":"the Joint Funds for the Innovation of Science and Technology, Fujian Province","award":["2020y9155"],"award-info":[{"award-number":["2020y9155"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-04045-2","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T17:33:14Z","timestamp":1763141594000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["WNT6 promotes choriocarcinoma progression by driving proliferation, invasion, and metastasis"],"prefix":"10.1007","volume":"16","author":[{"given":"Meilian","family":"Peng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianfu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caijin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengyu","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaodan","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qibin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,14]]},"reference":[{"key":"4045_CR1","volume-title":"Female genital tumours: WHO classification of tumours","author":"WHO Classification of Tumours Editorial Board","year":"2020","unstructured":"WHO Classification of Tumours Editorial Board. Female genital tumours: WHO classification of tumours. France: Lyon; 2020."},{"issue":"1","key":"4045_CR2","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ygyno.2015.11.014","volume":"140","author":"YK Eysbouts","year":"2016","unstructured":"Eysbouts YK, Bulten J, Ottevanger PB, Thomas CM, Kate-Booij T, van Herwaarden MJ, Siebers AE, Sweep AG, F. C., Massuger LF. Trends in incidence for gestational trophoblastic disease over the last 20 years in a population-based study. Gynecol Oncol. 2016;140(1):70\u20135. https:\/\/doi.org\/10.1016\/j.ygyno.2015.11.014.","journal-title":"Gynecol Oncol"},{"issue":"11","key":"4045_CR3","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1007\/s11912-014-0408-y","volume":"16","author":"FE Froeling","year":"2014","unstructured":"Froeling FE, Seckl MJ. Gestational trophoblastic tumours: an update for 2014. Curr Oncol Rep. 2014;16(11):408. https:\/\/doi.org\/10.1007\/s11912-014-0408-y.","journal-title":"Curr Oncol Rep"},{"issue":"10","key":"4045_CR4","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1055\/s-0035-1558054","volume":"75","author":"FT Stevens","year":"2015","unstructured":"Stevens FT, Katzorke N, Tempfer C, Kreimer U, Bizjak GI, Fleisch MC, Fehm TN. Gestational trophoblastic disorders: an update in 2015. Geburtshilfe Frauenheilkd. 2015;75(10):1043\u201350. https:\/\/doi.org\/10.1055\/s-0035-1558054.","journal-title":"Geburtshilfe Frauenheilkd"},{"issue":"1","key":"4045_CR5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1097\/GCO.0000000000000674","volume":"33","author":"JJ Clark","year":"2021","unstructured":"Clark JJ, Slater S, Seckl MJ. Treatment of gestational trophoblastic disease in the 2020s. Curr Opin Obstet Gynecol. 2021;33(1):7\u201312. https:\/\/doi.org\/10.1097\/GCO.0000000000000674.","journal-title":"Curr Opin Obstet Gynecol"},{"issue":"1Suppl 1","key":"4045_CR6","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1002\/ijgo.13877","volume":"155","author":"HYS Ngan","year":"2021","unstructured":"Ngan HYS, Seckl MJ, Berkowitz RS, Xiang Y, Golfier F, Sekharan PK, Lurain JR, Massuger L. Diagnosis and management of gestational trophoblastic disease: 2021 update. Int J Gynaecol Obstet. 2021;155(1Suppl 1):86\u201393. https:\/\/doi.org\/10.1002\/ijgo.13877.","journal-title":"Int J Gynaecol Obstet"},{"key":"4045_CR7","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.bpobgyn.2021.01.005","volume":"74","author":"A Braga","year":"2021","unstructured":"Braga A, Elias KM, Horowitz NS, Berkowitz RS. Treatment of high-risk gestational trophoblastic neoplasia and chemoresistance\/relapsed disease. Best Pract Res Clin Obstet Gynaecol. 2021;74:81\u201396. https:\/\/doi.org\/10.1016\/j.bpobgyn.2021.01.005.","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"issue":"8","key":"4045_CR8","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1007\/s11864-024-01235-y","volume":"25","author":"X Wang","year":"2024","unstructured":"Wang X, Wu J, Xie W. Evolution of treatment strategies for gestational trophoblastic neoplasia: Chemotherapy, Immunotherapy, and molecular targeted therapy. Curr Treat Options Oncol. 2024;25(8):1055\u201362. https:\/\/doi.org\/10.1007\/s11864-024-01235-y.","journal-title":"Curr Treat Options Oncol"},{"issue":"1","key":"4045_CR9","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1158\/1078-0432.CCR-23-2293","volume":"30","author":"SP Patel","year":"2024","unstructured":"Patel SP, Othus M, Chae YK, Dennis MJ, Gordon S, Mutch D, Samlowski W, Robinson WRR, Sharon E, Ryan C, Lopez G, Plets M, Blanke C, Kurzrock R. A phase II basket trial of dual Anti-CTLA-4 and Anti-PD-1 Blockade in rare tumors (DART SWOG 1609 cohort 47) in patients with gestational trophoblastic neoplasia. Clin Cancer Res. 2024;30(1):33\u20138. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-2293.","journal-title":"Clin Cancer Res"},{"issue":"5 Pt 2","key":"4045_CR10","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1016\/s0029-7844(02)02619-4","volume":"101","author":"N Esfandiari","year":"2003","unstructured":"Esfandiari N, Goldberg JM. Heterophile antibody blocking agent to confirm false positive serum human chorionic gonadotropin assay. Obstet Gynecol. 2003;101(5 Pt 2):1144\u20136. https:\/\/doi.org\/10.1016\/s0029-7844(02)02619-4.","journal-title":"Obstet Gynecol"},{"issue":"5 Pt 1","key":"4045_CR11","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/s0029-7844(01)01585-x","volume":"98","author":"TG Olsen","year":"2001","unstructured":"Olsen TG, Hubert PR, Nycum LR. Falsely elevated human chorionic gonadotropin leading to unnecessary therapy. Obstet Gynecol. 2001;98(5 Pt 1):843\u20135. https:\/\/doi.org\/10.1016\/s0029-7844(01)01585-x.","journal-title":"Obstet Gynecol"},{"issue":"6","key":"4045_CR12","doi-asserted-by":"publisher","first-page":"439","DOI":"10.3109\/09513590.2015.1132303","volume":"32","author":"B Gonz\u00e1lez Aguilera","year":"2016","unstructured":"Gonz\u00e1lez Aguilera B, Syrios P, Gadisseur R, Luyckx F, Cavalier E, Beckers A, Valdes-Socin H. Persistent low levels of serum hCG due to heterophilic mouse antibodies: an unrecognized pitfall in the diagnosis of trophoblastic disease. Gynecol Endocrinol. 2016;32(6):439\u201341. https:\/\/doi.org\/10.3109\/09513590.2015.1132303.","journal-title":"Gynecol Endocrinol"},{"issue":"2","key":"4045_CR13","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.ejogrb.2009.08.009","volume":"147","author":"J Seror","year":"2009","unstructured":"Seror J, Chabbert-Buffet N, Millot F, Lahlou N, Uzan S, Berkane N. False-positive immunometric assay results in the detection of Phantom human chorionic gonadotropin: a situation with possible severe iatrogenic consequences. Eur J Obstet Gynecol Reprod Biol. 2009;147(2):239\u201340. https:\/\/doi.org\/10.1016\/j.ejogrb.2009.08.009.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"2","key":"4045_CR14","first-page":"136","volume":"71","author":"M Zavadil","year":"2006","unstructured":"Zavadil M, Feyereisl J, Saf\u00e1r P, P\u00e1n M, Turyna R. Syndrom perzistuj\u00edc\u00edch n\u00edzk\u00fdch Hladin hum\u00e1nn\u00edch choriov\u00fdch gonadotropin\u016f (hCG) etiologie, klasifikace, diagnostika, postupy [Syndrome of persistent low levels of human chorionic gonadotrophin (hCG)]. Ceska Gynekol. 2006;71(2):136\u201342.","journal-title":"Ceska Gynekol"},{"issue":"3","key":"4045_CR15","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/onc.2012.40","volume":"32","author":"G Yuan","year":"2013","unstructured":"Yuan G, Regel I, Lian F, Friedrich T, Hitkova I, Hofheinz RD, Str\u00f6bel P, Langer R, Keller G, R\u00f6cken C, Zimmermann W, Schmid RM, Ebert MP, Burgermeister E. WNT6 is a novel target gene of caveolin-1 promoting chemoresistance to epirubicin in human gastric cancer cells. Oncogene. 2013;32(3):375\u201387. https:\/\/doi.org\/10.1038\/onc.2012.40.","journal-title":"Oncogene"},{"issue":"6","key":"4045_CR16","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1002\/1878-0261.12633","volume":"14","author":"CS Gon\u00e7alves","year":"2020","unstructured":"Gon\u00e7alves CS, Xavier-Magalh\u00e3es A, Martins EP, Pinto AA, Pires MM, Pinheiro C, Reis RM, Sousa N, Costa BM. A novel molecular link between HOXA9 and WNT6 in glioblastoma identifies a subgroup of patients with particular poor prognosis. Mol Oncol. 2020;14(6):1224\u201341. https:\/\/doi.org\/10.1002\/1878-0261.12633.","journal-title":"Mol Oncol"},{"issue":"1\u20132","key":"4045_CR17","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1007\/s10495-021-01704-x","volume":"27","author":"Z Ma","year":"2022","unstructured":"Ma Z, Cai S, Xiong Q, Liu W, Xia H, Zhu Z, Huang Z, Yan X, Wang Q. WNT signaling modulates chemoresistance to Temozolomide in p53-mutant glioblastoma multiforme. Apoptosis: Int J Program Cell Death. 2022;27(1\u20132):80\u20139. https:\/\/doi.org\/10.1007\/s10495-021-01704-x.","journal-title":"Apoptosis: Int J Program Cell Death"},{"key":"4045_CR18","doi-asserted-by":"publisher","first-page":"146871","DOI":"10.1016\/j.gene.2022.146871","volume":"846","author":"H Bao","year":"2022","unstructured":"Bao H, Wu W, Li Y, Zong Z, Chen S. WNT6 participates in the occurrence and development of ovarian cancer by upregulating\/activating the typical Wnt pathway and Notch1 signaling pathway. Gene. 2022;846:146871. https:\/\/doi.org\/10.1016\/j.gene.2022.146871.","journal-title":"Gene"},{"issue":"1","key":"4045_CR19","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.ygyno.2016.08.330","volume":"144","author":"J Brown","year":"2017","unstructured":"Brown J, Naumann RW, Seckl MJ, Schink J. 15years of progress in gestational trophoblastic disease: Scoring, standardization, and salvage. Gynecol Oncol. 2017;144(1):200\u20137. https:\/\/doi.org\/10.1016\/j.ygyno.2016.08.330.","journal-title":"Gynecol Oncol"},{"issue":"4","key":"4045_CR20","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1007\/s12094-022-03021-4","volume":"25","author":"Q Wu","year":"2023","unstructured":"Wu Q, Peng M, Lv C, Chen L, Mao X, Lin T, Sun P, Wang Y. Claudin-6 enhances the malignant progression of gestational trophoblastic neoplasm by promoting proliferation and metastasis. Clin Transl Oncol. 2023;25(4):1114\u201323. https:\/\/doi.org\/10.1007\/s12094-022-03021-4.","journal-title":"Clin Transl Oncol"},{"issue":"10","key":"4045_CR21","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1158\/2159-8290.CD-21-0190","volume":"11","author":"MJ Parsons","year":"2021","unstructured":"Parsons MJ, Tammela T, Dow LE. WNT as a driver and dependency in cancer. Cancer Discov. 2021;11(10):2413\u201329. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-0190.","journal-title":"Cancer Discov"},{"issue":"2","key":"4045_CR22","doi-asserted-by":"publisher","first-page":"875","DOI":"10.3892\/or.2018.6914","volume":"41","author":"N Li","year":"2019","unstructured":"Li N, Li D, Du Y, Su C, Yang C, Lin C, Li X, Hu G. Overexpressed PLAGL2 transcriptionally activates Wnt6 and promotes cancer development in colorectal cancer. Oncol Rep. 2019;41(2):875\u201384. https:\/\/doi.org\/10.3892\/or.2018.6914.","journal-title":"Oncol Rep"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-04045-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-04045-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-04045-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T03:02:57Z","timestamp":1765940577000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-04045-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,14]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4045"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-04045-2","relation":{},"ISSN":["2730-6011"],"issn-type":[{"type":"electronic","value":"2730-6011"}],"subject":[],"published":{"date-parts":[[2025,11,14]]},"assertion":[{"value":"29 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of the College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University (No. 2021KLRD09052).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and content to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2201"}}